What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Internal medicine, Lung cancer, Cancer research, Cancer and Oncology are his primary areas of study.
His work on Immunotherapy, Carcinoma, Vismodegib and Phases of clinical research as part of general Internal medicine research is frequently linked to Response Evaluation Criteria in Solid Tumors, bridging the gap between disciplines.
The Lung cancer study combines topics in areas such as Survival rate, Surgery, Immunology, KRAS and Hazard ratio.
His research integrates issues of Cell culture, Endocrinology, Cisplatin, EZH2 and Regulation of gene expression in his study of Cancer research.
He has included themes like Gastroenterology, Adverse effect and Pathology, Histology in his Cancer study.
Charles M. Rudin combines subjects such as Clinical endpoint, Clinical trial, Blockade, Nivolumab and Adenocarcinoma with his study of Oncology.
His most cited work include:
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer (5007 citations)
- Akt stimulates aerobic glycolysis in cancer cells (1130 citations)
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs (931 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Cancer research, Oncology, Lung cancer and Cancer.
His research combines Surgery and Internal medicine.
His Cancer research research is multidisciplinary, incorporating elements of Cell, Carcinogenesis, Immunology, Pathology and In vivo.
In the field of Oncology, his study on Non small cell overlaps with subjects such as In patient.
His studies in Lung cancer integrate themes in fields like Mutation, KRAS, Carcinoma, Targeted therapy and Adenocarcinoma.
As part of his studies on Cancer, he frequently links adjacent subjects like Disease.
He most often published in these fields:
- Internal medicine (45.80%)
- Cancer research (47.38%)
- Oncology (38.46%)
What were the highlights of his more recent work (between 2019-2021)?
- Cancer research (47.38%)
- Internal medicine (45.80%)
- Oncology (38.46%)
In recent papers he was focusing on the following fields of study:
His main research concerns Cancer research, Internal medicine, Oncology, Lung cancer and Cancer.
Charles M. Rudin interconnects Cell, ASCL1, Metastasis, PI3K/AKT/mTOR pathway and Adenocarcinoma in the investigation of issues within Cancer research.
The various areas that Charles M. Rudin examines in his Oncology study include Pembrolizumab, Clinical trial, Disease and Exon.
He has included themes like Mutation, KRAS, STK11, Mutant and Germline in his Lung cancer study.
The Cancer study combines topics in areas such as Lineage and Computational biology.
His Immunotherapy study incorporates themes from Biomarker and Antigen presentation.
Between 2019 and 2021, his most popular works were:
- Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers (83 citations)
- Regenerative lineages and immune-mediated pruning in lung cancer metastasis (71 citations)
- The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution (65 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
His primary scientific interests are in Internal medicine, Cancer research, Lung cancer, Oncology and Cancer.
His Cancer research research integrates issues from Immunohistochemistry, Trastuzumab, Cellular differentiation, Tumor progression and Internalization.
The study incorporates disciplines such as Tyrosine kinase, Receptor, Endocytosis, Mutant and Cytotoxic T cell in addition to Lung cancer.
His work carried out in the field of Oncology brings together such families of science as Concurrent chemoradiation, Blockade and Immunotherapy.
He has researched Immunotherapy in several fields, including Mutation, Missense mutation, KRAS, STK11 and Biomarker.
The concepts of his Cancer study are interwoven with issues in Exosome, Cell and Proteomic Profile.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
